Skye Bioscience, Inc. — Director's Dealing 2023

Mar 17, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Skye Bioscience, Inc. (SKYE)
CIK: 0001516551
Period of Report: 2022-11-10

Reporting Person: Emerald Health Sciences Inc. (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-02-22	Common Stock	A	16641486	$0.017	Acquired	128028737	Direct
2023-02-22	Common Stock	A	41379164	$0.0386	Acquired	169407901	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-11-10	Warrants	$0.151	J	9141486	Acquired	2024-12-30	Common Stock (9141486)	Direct
2023-02-22	Warrants	$0.017	D	9141486	Disposed	2024-12-30	Common Stock (9141486)	Direct
2023-02-22	Warrants with Credit Facility of Oct 5, 2018	$0.0386	P	2500000	Disposed	2023-11-01	Common Stock (2500000)	Direct
2023-02-22	Warrants with Credit Facility of Oct 5, 2018 - T2	$0.0386	D	2500000	Disposed	2024-02-01	Common Stock (2500000)	Direct
2023-02-22	Warrants with Credit Facility of Oct 5, 2018 - T3	$0.0386	D	2500000	Disposed	2024-03-29	Common Stock (2500000)	Direct

Footnotes

F1: Warrants were acquired pursuant to a merger between Issuer and Emerald Health Therapeutics, Inc. ("Emerald"), whereby Reporting Person's outstanding warrants to purchase Emerald common stock were exchanged for warrants to purchase Issuer common stock.

F2: Aggregate exercise price for the warrants was paid through a reduction in the debt Issuer owed to Reporting Person under the Multi Draw Credit Facility.